



FINANCIAL TEAR SHEET

Corporate Profile


Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Stock Information

JNCE (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$8.37
Change (%)	▲ 0.22 (2.70%)
Volume	136,826
52 Week Low	\$6.92
Market Cap	\$264,740,052
Rolling EPS	-0.93
PE Ratio	0
Shares Outstanding	32,483,442

Data as of 06/22/18 1:09 p.m. ET



Recent Headlines & Events

06/02/18 - 4:00 p.m.

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

There are currently no events scheduled.

05/16/18 - 5:01 p.m.

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

05/09/18 - 6:30 a.m.

Jounce Therapeutics Reports First Quarter 2018 Financial Results

SEC Filings

FILING DATE	FORM
06/21/18	4
06/21/18	4
06/21/18	4
06/21/18	4

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.